Turkey's breast cancer therapeutics market is expected to witness growth from $146 Mn in 2022 to $398 Mn in 2030 with a CAGR of 13.4% for the forecasted year 2022-30 due to rapid advancements in research and development initiatives in Turkey. The market is segmented by therapy, by cancer type, and by distribution channel. EastPharma, Gensenta Pharmaceuticals, and Bristol-Myers Squibb are some of the leading market players in Turkey's breast cancer therapeutics market.
Turkey's breast cancer therapeutics market size is at around $146 Mn in 2022 and is projected to reach $398 Mn in 2030, exhibiting a CAGR of 13.4% during the forecast period. In 2020, total health spending in Turkey climbed by 24.3% over the previous year to reach $13,291 Bn. The overall government's health spending increased by 26.3% to $1,056 Bn. The expected cost of healthcare in the private sector was $2,758 Bn, a rise of 17.3%. 2020 saw an increase in current health spending of 23.8% over 2019 to reach $1242 Bn. Investments in healthcare expenses increased by 31.9% to reach $897 Bn.
In Turkey, breast cancer affects more women than any other type of cancer. The incidence of breast cancer varies by region, according to the national data. In the western portion of Turkey, the incidence is 50/100.000, whereas, in the eastern part, it is 20/100.000. In addition, among Turkish women, breast cancer ranks 1 in terms of cancer-related deaths. In Turkey, there isn't a systematic national mammography screening programme. More than 10,000 women between the ages of 40 and 69 participated in Istanbul's Bahcesehir County's first and ongoing coordinated population-based screening programme, which began in 2008. In surgery, the entire breast (mastectomy), the area where the tumour is located, or just the tumour itself (lumpectomy) may be removed. Mastectomy is now viewed as the last resort as lumpectomy is favoured. Neoadjuvant chemotherapy is administered to some patients to minimize tumour burden and simplify surgical procedures. Adjuvant chemotherapy is given to some patients to increase survival and decrease the risk of recurrence after surgery. According to recent studies in Turkey, cryoablation and radiofrequency are also identified as new treatment options for breast cancer.
Market Growth Drivers
Leading firms in Turkey are projected to increase their research and development efforts in order to launch a recognised and efficient breast cancer treatment, which will serve as a market driver for Turkey's breast cancer therapeutics market.
Market Restraints
High treatment costs in Turkey and the termination of late-stage clinical studies are anticipated to have a significant negative impact on Turkey's breast cancer therapeutics market.
Key Players
There is public health insurance for everyone in Turkey. Free healthcare is available to all inhabitants who have registered with the Social Security Institution (SSI). The Ministry of Health (MoH) controls more than half of hospitals and sets health policies. The SSI contracts with service providers, collects and pools social security premiums, and establishes prices for medical services. Governmental organisations are in charge of other duties like workforce planning and the control of medications and medical devices. For primary, secondary, and tertiary medical services, patients are required to make co-payments at various levels. In order to help low-income individuals with breast cancer pay for their treatment, the government offers financial assistance.
1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
By Therapy (Revenue, USD Billion):
By Cancer Type (Revenue, USD Billion):
By Distribution Channel (Revenue, USD Billion):
Methodology for Database Creation
Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.
Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.
How Do We Get It?
Our database is created and maintained through a combination of secondary and primary research methodologies.
1. Secondary Research
With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:
With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:
2. Primary Research
To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:
Combining Secondary and Primary Research
By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:
Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.